Skip to content

Living with low testosterone: Long-term management and outcomes

Vladimir Kotlov, MD avatar
Vladimir Kotlov, MD: Founder & CEO at Veedma
Oct 09, 2026 · 15 min read

Listen to this article as a podcast episode

August 28, 2026 · 21:17

Living with low testosterone usually means long term monitoring, because male hypogonadism is a clinical syndrome defined by persistent symptoms plus biochemical deficiency. The long term plan depends on whether the problem is functional and potentially reversible, or organic and usually permanent. That distinction determines prognosis, whether treatment may be stopped, and how testosterone therapy long term should be monitored.

Find the cause before treating it

Choose a lab panel and get a clinical review with clear next steps.

Order your lab panel

Key takeaways

  • Low testosterone is not diagnosed by a lab number alone. Persistent symptoms must coexist with testosterone that is consistently low on repeat morning testing.[1]
  • LH and FSH should be measured with testosterone to find the cause. High LH plus low testosterone indicates primary hypogonadism, while low or normal LH plus low testosterone indicates secondary hypogonadism, and the two are treated differently.[1]
  • In men with obesity related low testosterone, weight loss raises testosterone and gonadotropins, so functional hypogonadism may not require lifelong treatment.[2] Organic hypogonadism, including Klinefelter syndrome, post chemotherapy testicular failure, and post surgical causes, is usually lifelong.
  • Stopping TRT and stopping Enclomiphene are not equivalent. TRT suppresses sperm production, while Enclomiphene raised LH and FSH and conserved sperm counts in a randomized trial, so stopping it does not involve recovery from a suppressed axis.[3] [4]
  • Long term TRT management needs a standing monitoring plan: symptoms, adverse effects, testosterone, hematocrit, and prostate cancer risk, with the closest follow up during the first year.[1]
  • Low testosterone is associated in observational studies with higher all cause and cardiovascular mortality, while randomized data show testosterone replacement therapy was noninferior to placebo for major cardiovascular events over a mean 33 month follow up in 5,246 men.[5] [6] [7]

What is the long term prognosis of low testosterone?

Low testosterone is associated in observational studies with higher all cause and cardiovascular mortality. These studies cannot show that low testosterone itself causes the excess risk.[5] [8]

Prognosis means the expected course of health over time. In men with low testosterone, that course is not uniform. A man with reversible, functional hypogonadism caused by obesity or metabolic disease has a different low testosterone prognosis from a man with primary testicular failure after chemotherapy or from a man with Klinefelter syndrome. According to the Endocrine Society guideline, the diagnosis should rest on symptoms and consistently low testosterone on repeat fasting morning tests, followed by an evaluation of the cause, not on a single number in isolation.[1]

Mortality and cardiovascular risk

Observational evidence links low endogenous testosterone with worse survival. A 2011 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that low testosterone was associated with higher all cause and cardiovascular mortality in community based studies of men.[5] Results varied widely between studies, which suggests that differences in underlying health explain part of the link.[5] A 2010 study in Heart followed 930 men with coronary disease for a mean of 6.9 years.[6] Deaths occurred in 21 percent of androgen deficient men versus 12 percent of the others, and low bioavailable testosterone was independently associated with about twice the risk of death.[6] A 2014 review in Clinical Endocrinology described the same pattern in men with cardiovascular, respiratory, and renal disease, type 2 diabetes, and cancer.[8] It concluded that low testosterone is a convincing marker of disease severity and mortality.[8]

These data do not prove that testosterone deficiency alone causes these deaths. Low testosterone often travels with obesity, diabetes, cardiovascular disease, and inflammatory illness. Whether treatment improves survival remains unsettled. Two retrospective studies in men with diagnosed hypogonadism, with or without type 2 diabetes, reported better survival on testosterone. Randomized trials have not been designed to test that endpoint, so the signal is an association rather than proof of benefit.[8]

Quality of life and daily function

In older men, testosterone treatment improved some aspects of daily life but not others.[9]

The Testosterone Trials, published in 2016 in the New England Journal of Medicine, randomized 790 men aged 65 or older with testosterone below 275 ng/dL and symptoms of deficiency to testosterone gel or placebo for 1 year.[9] Treatment moderately improved sexual activity, sexual desire, and erectile function, and it slightly improved mood and depressive symptoms. It did not improve vitality or walking distance in the physical function trial.[9] Individual responses should be interpreted through the correct diagnosis. A man whose axis is suppressed by obesity or medication may recover differently from a man whose testes cannot respond at all.

That is why long term TRT management starts with classification. For the diagnostic framework behind that distinction, see Primary vs secondary hypogonadism: where the problem starts and why it changes everything.

Who needs lifelong treatment and who may not?

Functional hypogonadism may improve or even normalize if the suppressive cause is corrected. In men with obesity, weight loss raises both testosterone and gonadotropins.[2] Organic hypogonadism is usually lifelong and managed for maintenance rather than restoration.

Functional hypogonadism means low testosterone caused by reversible suppression of an otherwise intact HPG axis. The HPG axis is the hormone signaling pathway that runs from the hypothalamus to the pituitary to the testes. Organic hypogonadism means structural or permanent disease in the testes or pituitary. That distinction matters more than the starting testosterone value alone.

Functional hypogonadism has a different outlook

According to the Endocrine Society guideline, men found to have androgen deficiency should have further evaluation to identify its cause.[1] Reversible drivers such as obesity, type 2 diabetes, and certain medications can suppress the axis, and testosterone can rise when they improve. A 2013 meta-analysis in the European Journal of Endocrinology found that weight loss raised testosterone in obese men.[2] The rise was modest after a low calorie diet and larger after bariatric surgery, and it was greater in men who lost more weight.[2]

The challenge is durability. About 60 to 86 percent of lost weight is regained within 3 years, and when the weight returns, the hormonal suppression can return with it. The most common real world pattern is partial improvement, relapse, and the need for ongoing care.

Enclomiphene is one treatment studied in men with secondary hypogonadism and an intact axis. It blocks estrogen feedback at the hypothalamus, which raises LH and FSH and stimulates the testes to make more of their own testosterone. A 2014 randomized phase II trial in Fertility and Sterility found that enclomiphene raised morning testosterone to levels similar to topical testosterone gel, increased LH and FSH, and conserved sperm counts.[4] Because it does not shut down the axis, a man whose weight, sleep, or medication exposure improves can try stopping it without first recovering from suppression.

Organic hypogonadism is usually a maintenance condition

Organic hypogonadism is typically lifelong because the tissue responsible for testosterone production or regulation is permanently damaged.

Examples include Klinefelter syndrome, post chemotherapy testicular failure, bilateral testicular injury, congenital gonadal disorders, and some post surgical states. In these men, treatment goals shift. The objective is no longer to “restart” a suppressed system. It is to maintain symptom control, bone health, body composition, sexual function, and overall health as steadily as possible over years or decades.

A man’s low testosterone prognosis therefore depends on cause as much as severity. For the full reversible versus permanent framework, see Functional vs organic hypogonadism: is your low T reversible?.

What happens if you stop treatment?

Stopping TRT and stopping Enclomiphene have different biological consequences. TRT suppresses endogenous signaling and sperm production, while Enclomiphene raises LH and FSH.[3] [4]

Whether a man can come off treatment later depends on the original diagnosis and on what the treatment has done to the axis over time.

Stopping TRT

With testosterone replacement therapy, the body receives exogenous testosterone, meaning testosterone supplied from outside the body. That raises serum testosterone, but it also feeds back to the brain and suppresses LH and FSH, which reduces sperm production. A 2015 review in Current Opinion in Obstetrics and Gynecology noted that many clinicians and men with hypogonadism do not recognize this effect on spermatogenesis, and that sperm production recovers for most men after treatment stops.[3] For the same reason, the Endocrine Society guideline recommends against starting testosterone therapy in men planning fertility in the near term.[1]

For a man with primary hypogonadism, stopping TRT usually means returning to the untreated hypogonadal state because the testes were never capable of adequate output. For a man with secondary or functional hypogonadism, recovery of testosterone after stopping TRT is variable. Natural production may return, partly return, or remain inadequate for a prolonged period. Symptoms often recur if the original cause has not resolved.

Stopping Enclomiphene

With Enclomiphene, testosterone rises because the man’s own testes are stimulated through LH and FSH signaling, so the axis keeps working throughout treatment.[4] If the underlying suppressive cause has improved, testosterone may stay at a better level after therapy stops. If the cause is still present, testosterone may fall again, but without the added problem of recovering from TRT induced shutdown. Data on long term use and on testosterone levels after stopping are limited.

QuestionEnclomipheneTRT
What happens to LH and FSH during treatment?They usually remain active or riseThey are suppressed
What happens to fertility?Spermatogenesis is generally preservedSpermatogenesis is suppressed
What if the underlying cause improves?A trial off therapy is often reasonableRecovery is uncertain because the axis has been suppressed
What if the underlying cause does not improve?Testosterone usually falls again, but the axis remains more intactSymptoms usually return and endogenous recovery may be incomplete
Best fitSecondary or functional hypogonadism with intact testesPrimary hypogonadism, or secondary hypogonadism that does not respond to Enclomiphene

For men who may want children or may later want to stop treatment, this difference weighs as heavily in the choice of first therapy as any short term symptom gain.

How is long term TRT management done?

Long term TRT management requires a standardized plan that evaluates symptoms, adverse effects, and adherence, measures testosterone and hematocrit, and assesses prostate cancer risk.[1]

What must be monitored

According to the Endocrine Society guideline, men on testosterone need structured follow up of testosterone levels, hematocrit, symptoms, and prostate cancer risk, with the closest monitoring during the first year after starting therapy.[1] Hematocrit is the percentage of blood volume made up by red blood cells. Erythrocytosis, meaning an abnormally high red cell concentration, is the most common adverse effect of testosterone therapy, and the guideline advises pausing treatment if hematocrit rises above 54 percent.[1]

  • Testosterone level, with free testosterone checked when changes in SHBG may hide deficiency
  • Hematocrit and CBC
  • PSA and prostate screening by age appropriate guidance
  • Lipid and glycemic profile
  • Cardiovascular risk assessment
  • Bone density when hypogonadism is severe or prolonged

Hematocrit deserves particular attention between 3 and 12 months of treatment. Over the longer term, the same labs often detect cardiometabolic disease early, which is one reason annual review of broader health risks remains useful.

What the best TRT long term outcomes data show

The TRAVERSE trial, published in 2023 in the New England Journal of Medicine, randomized 5,246 men aged 45 to 80 to testosterone gel or placebo.[7] All participants had symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and existing or high risk of cardiovascular disease. Over a mean follow up of 33 months, a major cardiovascular event occurred in 7.0 percent of the testosterone group and 7.3 percent of the placebo group, meeting the criterion for noninferiority. Atrial fibrillation, acute kidney injury, and pulmonary embolism were more frequent with testosterone.[7] The trial does not show that testosterone is risk free or that monitoring can stop. It does show that the old blanket statement that TRT is inherently cardiotoxic is not supported by the largest randomized dataset available.

Long term management also has a symptom target. The Testosterone Trials found a moderate benefit for sexual function and some benefit for mood, but none for vitality.[9] If testosterone levels are in the target range and the man does not feel better, the plan should not simply be “increase dose.” The diagnosis needs to be reassessed.

How does aging change testosterone therapy long term?

Aging changes testosterone therapy long term because SHBG tends to rise, comorbidities accumulate, and medication interactions become more common over time.

SHBG is the liver made protein that binds testosterone in the bloodstream. As SHBG rises, total testosterone can look acceptable while free testosterone is low. The Endocrine Society guideline recommends measuring free testosterone by equilibrium dialysis, or estimating it with an accurate formula, when total testosterone is near the lower limit of normal or a condition alters SHBG.[1]

In long term care, the protocol that worked at age 45 may not fit at age 65. A man may develop diabetes, sleep apnea, cardiovascular disease, polypharmacy, or prostate related symptoms that alter the risk benefit balance. Because weight loss raises testosterone in obesity related hypogonadism, managing obesity and other comorbidities belongs inside the treatment plan rather than alongside it.[2] Aging, body composition, sleep, new medications, and changing reproductive goals can all shift the right plan over time.

Why lifestyle and reassessment still matter

In obesity related functional hypogonadism, weight loss can raise testosterone on its own, which is why lifestyle measures and periodic diagnostic reassessment remain part of the plan during hormone treatment.[2]

In the weight loss meta-analysis, the degree of weight lost was the strongest predictor of the rise in testosterone, and gonadotropin levels rose as well.[2] Resistance training improves body composition. Better sleep supports nocturnal testosterone production. Dietary improvement helps insulin resistance and central adiposity, which in turn reduces ongoing suppression of the axis.

Because Enclomiphene leaves the axis active, a man with functional hypogonadism can treat symptoms while working on weight and metabolic health, then reassess whether medication is still needed. That is a different long term strategy from committing early to a replacement pathway that suppresses endogenous function.

When to reassess the diagnosis

If symptoms are not improving despite testosterone levels in the target range, the diagnosis should be revisited rather than assumed correct. The Endocrine Society guideline includes symptom evaluation in its standardized monitoring plan, alongside testosterone and hematocrit.[1]

Reassessment checks whether the original problem was truly hypogonadism, meaning symptoms plus biochemical deficiency, and whether LH and FSH were measured at the start. It also checks whether functional hypogonadism has been mistaken for permanent disease, and whether obesity, diabetes, sleep loss, or medication burden has worsened since treatment began. A treatment that does not deliver the expected benefit calls for review of the whole clinical picture, not reflex dose escalation.

For the lab strategy behind that review, see The complete low testosterone testing guide: what to order, when to test, and how to read results. If you are unsure whether the diagnosis itself was framed correctly, see What is low testosterone? The clinical definition most men and many doctors get wrong.

Myth vs fact

Myth: You always need lifelong treatment if testosterone is low

Fact: Functional hypogonadism may improve when its cause improves. In obese men, weight loss raises testosterone and gonadotropins.[2] That is why treatment selection should distinguish reversible suppression from permanent organ failure.

Myth: Stopping TRT is the same as stopping Enclomiphene

Fact: TRT suppresses LH, FSH, and sperm production, so endogenous recovery after stopping is variable. Enclomiphene raises LH and FSH and stimulates the man’s own testes, so stopping it does not require recovery from suppression when the underlying cause has improved.[3] [4]

Myth: Once symptoms improve, monitoring can be relaxed

Fact: Long term TRT management never becomes optional. Symptoms, testosterone, hematocrit, and prostate cancer risk all require ongoing surveillance, with special attention during the first year.[1]

Myth: Lifestyle change does not matter after medication starts

Fact: Weight loss can raise testosterone in obesity related hypogonadism, and the gain is larger with greater weight loss.[2] Diet quality, resistance training, and sleep stay part of care at every stage, especially in functional hypogonadism.

Bottom line

Living with low testosterone is a long term clinical process, not a one time prescription. The outlook depends first on whether the condition is functional and reversible or organic and lifelong. Functional hypogonadism may improve enough to permit a trial off treatment once weight, sleep, metabolic health, and medication burden are addressed. Organic hypogonadism usually calls for steady maintenance and monitoring. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs a man already has. Licensed providers can prescribe Enclomiphene or the Enclomiphene plus tadalafil tablet when appropriate and monitor treatment over time. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

References

  1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
  2. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168:829-43. PMID: 23482592
  3. Owen RC, Elkelany OO, Kim ED. Testosterone supplementation in men: a practical guide for the gynecologist and obstetrician. Curr Opin Obstet Gynecol. 2015;27:258-64. PMID: 26107780
  4. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102:720-7. PMID: 25044085
  5. Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007-19. PMID: 21816776
  6. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821-5. PMID: 20959649
  7. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. PMID: 37326322
  8. Muraleedharan V, Jones TH. Testosterone and mortality. Clin Endocrinol (Oxf). 2014;81:477-87. PMID: 25041142
  9. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374:611-24. PMID: 26886521

Start with a lab panel

Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.

Order your lab panel

Prefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD

Vladimir Kotlov, MD: Founder & CEO at Veedma

Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.